Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatoblastoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Hepatoblastoma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-002925-29 Sponsor Protocol Number: 200605 Start Date*: 2005-09-20
    Sponsor Name:University Childrens Hospital
    Full Title: Irinotecan singele drug treatment for children with refractory or relapsed hepatoblastoma
    Medical condition: Refractory or recurrent hepatoblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001271-38 Sponsor Protocol Number: LT 2004 09 Start Date*: 2006-06-23
    Sponsor Name:Our Lady's Hospital for Sick Children
    Full Title: Intensified pre-operative chemotherapy and radical surgery for HIGH RISK HEPATOBLASTOMA SIOPEL 4
    Medical condition: Hepatoblastoma
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002402-21 Sponsor Protocol Number: RG_09-205 Start Date*: 2007-08-24
    Sponsor Name:University of Birmingham
    Full Title: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma
    Medical condition: Standard risk hepatoblatoma in children
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10019824 Hepatoblastoma resectable LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FR (Ongoing) IE (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003595-12 Sponsor Protocol Number: ADVL1322-VEG116731 Start Date*: 2013-09-04
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase II Study of Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors.
    Medical condition: relapsed solid tumours in children, adolescents and young adults.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA CZ (Completed) SK (Completed) ES (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019348-37 Sponsor Protocol Number: CLDE225X2104 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase 1 study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway
    Medical condition: pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway (rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066594 Medulloblastoma recurrent LLT
    12.1 10039027 Rhabdomyosarcoma recurrent LLT
    12.1 10066595 Neuroblastoma recurrent LLT
    12.1 10065443 Malignant glioma LLT
    12.1 10031296 Osteosarcoma recurrent LLT
    12.1 10019823 Hepatoblastoma recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2023-000036-30 Sponsor Protocol Number: NBK151/1/2022 Start Date*: 2023-08-31
    Sponsor Name:Medical University of Gdańsk
    Full Title: A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma.
    Medical condition: Hepatoblastoma and liver cancer (hepatocarcinoma)
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001830-34 Sponsor Protocol Number: 05LG12 Start Date*: 2005-08-18
    Sponsor Name:King's College Hospital
    Full Title: The use of Myfortic in paediatric patients after liver transplantation
    Medical condition: Liver transplantation
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002828-85 Sponsor Protocol Number: RG_15-114 Start Date*: 2017-04-28
    Sponsor Name:University of Birmingham
    Full Title: Paediatric Hepatic International Tumour Trial
    Medical condition: Hepatoblastoma and Hepatocellular Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062001 Hepatoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) DE (Ongoing) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) AT (Ongoing) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004529-14 Sponsor Protocol Number: VTL-308 Start Date*: 2016-02-08
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED, PIVOTAL STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD® IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-Induced Liver Decompensation (AILD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001884-21 Sponsor Protocol Number: VTI-210 Start Date*: 2013-07-26
    Sponsor Name:VITAL THERAPIES INCORPORATED
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH SEVERE ACUTE ALCOHOLIC HEPATITIS (SAAH) AND LILLE SCORE FAILURE
    Medical condition: Severe Acute Alcoholic Hepatitis (sAAH)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000591-42 Sponsor Protocol Number: JX594-IV-HEP021 Start Date*: 2012-09-21
    Sponsor Name:Jennerex, Inc
    Full Title: A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients with Advance...
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003946-99 Sponsor Protocol Number: GETHI021 Start Date*: 2017-06-19
    Sponsor Name:Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI)
    Full Title: A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood
    Medical condition: Pediatric solid tumors presenting in adulthood
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000085-32 Sponsor Protocol Number: TG6006.01 Start Date*: 2018-05-04
    Sponsor Name:TRANSGENE SA
    Full Title: A phase I/IIa trial to evaluate the safety and efficacy of the combination of the oncolytic immunotherapy Pexa-Vec with the PD-1 receptor blocking antibody nivolumab in the first-line treatment of ...
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001238-32 Sponsor Protocol Number: ADVL1622 Start Date*: 2019-09-26
    Sponsor Name:National Cancer Institute Cancer Therapy Evaluation
    Full Title: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
    Medical condition: Ewing sarcoma, Rhabdomyosarcoma, Non rhabdomyosarcoma, Wilms Tumor, Osteosarcoma and Other Rare Tumors
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-017793-20 Sponsor Protocol Number: CMMo/RH/2009 Start Date*: 2010-11-16
    Sponsor Name:Fundación Progreso y Salud
    Full Title: ENSAYO CLINICO FASE II MULTICÉNTRICO, ABIERTO Y ALEATORIZADO SOBRE EL USO TERAPEUTICO DE LA INFUSION INTRAPORTAL DE CÉLULAS MONONUCLEADAS DE MÉDULA ÓSEA AUTÓLOGA COMO POTENCIADOR DE LA REGENERACIÓN...
    Medical condition: Pacientes con lesión ocupante de espacio hepática (LOE) que precisen una resección hepática extendida
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003579-36 Sponsor Protocol Number: BAY73-4506/15906 Start Date*: 2018-01-15
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard...
    Medical condition: Pediatric patients with solid malignant tumors that are recurrent or refractory to standard therapy.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-003736-77 Sponsor Protocol Number: E7080-A001-216 Start Date*: 2023-03-28
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Medical condition: Recurrent and Refractory Solid Tumors
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005563-27 Sponsor Protocol Number: VTI-208 Start Date*: 2013-07-26
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-induced liver decompensation (AILD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001985-86 Sponsor Protocol Number: JX594-HEP024 Start Date*: 2016-09-29
    Sponsor Name:SillaJen Inc.
    Full Title: A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carc...
    Medical condition: Advanced Hepatocellular Carcinoma (HCC) without prior systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015002-19 Sponsor Protocol Number: VTI-206 Start Date*: 2010-01-18
    Sponsor Name:VITAL THERAPIES INCORPORATED
    Full Title: EFFICACY AND SAFETY OF ELAD IN SUBJECTS WITH ACUTE ON CHRONIC HEPATITIS (AOCH)
    Medical condition: Acute on Chronic Hepatitis (AOCH)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:26:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA